Evidence map›Paper›PMID 39796506›Full record

ArticleNutrients2024

Role of Increasing Body Mass Index in Gut Barrier Dysfunction, Systemic Inflammation, and Metabolic Dysregulation in Obesity.

Fatima Maqoud, Francesco Maria Calabrese, Giuseppe Celano, Domenica Mallardi, Francesco Goscilo, Benedetta D'Attoma, Antonia Ignazzi, Michele Linsalata, Gabriele Bitetto, Martina Di Chito and 7 more

Abstract read
In one paragraph

Article in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Elevated Markers of Intestinal Barrier Dysfunction and TLR2 Ligands in Individuals with Type 1 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Fatima MaqoudFunctional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.
Francesco Maria CalabreseDepartment of Soil, Plant and Food Science, University of Bari Aldo Moro, 70126 Bari, Italy.ORCID 0000-0003-0176-7046
Giuseppe CelanoDepartment of Soil, Plant and Food Science, University of Bari Aldo Moro, 70126 Bari, Italy.ORCID 0000-0002-3805-7681
Domenica MallardiFunctional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0002-0629-0972
Francesco GosciloFunctional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.ORCID 0009-0008-1129-0126
Benedetta D'AttomaFunctional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0002-5416-3521
Antonia IgnazziFunctional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.
Michele LinsalataFunctional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0001-7350-2544
Gabriele BitettoCenter of Nutrition for the Research and the Care of Obesity and Metabolic Diseases, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.
Martina Di ChitoCenter of Nutrition for the Research and the Care of Obesity and Metabolic Diseases, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.
Pasqua Letizia PesoleCore Facility Biobank, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0003-4675-2075
Arianna DiciollaLaboratory of Clinical Pathology, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.
Carmen Aurora ApaDepartment of Soil, Plant and Food Science, University of Bari Aldo Moro, 70126 Bari, Italy.ORCID 0009-0002-4898-9850
Giovanni De PergolaCenter of Nutrition for the Research and the Care of Obesity and Metabolic Diseases, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0003-0020-3273
Gianluigi GiannelliScientific Direction, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0002-5140-8060
Maria De AngelisDepartment of Soil, Plant and Food Science, University of Bari Aldo Moro, 70126 Bari, Italy.ORCID 0000-0002-2010-884X
Francesco RussoFunctional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Castellana Grotte, 70013 Bari, Italy.ORCID 0000-0003-0538-6072

Funding

Italian Ministry of Health RC 2022-2024 DDG no. 700/2020
6 · The paper itself

Abstract

aimsThis study explores the link between body mass index (BMI), intestinal permeability, and associated changes in anthropometric and impedance parameters, lipid profiles, inflammatory markers, fecal metabolites, and gut microbiota taxa composition in participants having excessive body mass.

methodsA cohort of 58 obese individuals with comparable diet, age, and height was divided into three groups based on a priori clustering analyses that fit with BMI class ranges: Group I (25-29.9), Group II (30-39.9), and Group III (>40). Anthropometric and clinical parameters were assessed, including plasma C-reactive protein and cytokine profiles as inflammation markers. Intestinal permeability was measured using a multisaccharide assay, with fecal/serum zonulin and serum claudin-5 and claudin-15 levels. Fecal microbiota composition and metabolomic profiles were analyzed using a phylogenetic microarray and GC-MS techniques.

resultsThe statistical analyses of the clinical parameters were based on the full sample set, whereas a subset composed of 37 randomized patients was inspected for the GC/MS metabolite profiling of fecal specimens. An increase in potentially pro-inflammatory bacterial genera (e.g.,

conclusionsTogether, these data demonstrated how an increased BMI led to significant changes in inflammatory markers, intestinal barrier metabolites, glucose metabolism, endocrine indicators, and fecal metabolomic profiles that can indicate a different metabolite production from gut microbiota. Our findings suggest that targeting intestinal permeability may offer a therapeutic approach to prevent and manage obesity and related metabolic complications, reinforcing the link between gut barrier function and obesity.

Indexed as

Body Mass IndexGastrointestinal MicrobiomeInflammationIntestinal MucosaObesityAdultBiomarkersC-Reactive ProteinFecesFemaleHumansMaleMiddle AgedPermeabilityBiomarkersC-Reactive Proteinbody mass index (BMI)fecal metabolomicsfecal microbiotainflammatory markersintestinal permeabilityobesityzonulin

Identifiers

PMID39796506
PMCPMC11723324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.